[Embolization of spontaneous portosystemic shunts as treatment for refractory hepatic encephalopathy]

Rev Med Chil. 2022 Jul;150(7):879-888. doi: 10.4067/s0034-98872022000700879.
[Article in Spanish]

Abstract

Background: Hepatic encephalopathy (HE) is a common complication of cirrhosis associated with a reduced survival. The presence of high-flux spontaneous porto-systemic shunts can induce HE even in patients with preserved liver function.

Aim: To evaluate the effect of spontaneous porto-systemic shunt embolization (SPSE) over HE and its long-term evolution.

Material and methods: Retrospective analysis of 11 patients (91% males) with severe HE non-responsive to medical treatment in whom a SPSE was performed. The grade of HE (employing West Haven score), survival, MELD and Child-Pugh score, ammonia levels, degree of disability (employing the modified Rankin scale (mRs)) were evaluated before and at thirty days after procedure.

Results: The most common etiology found was non-alcoholic steatohepatitis (63.6%). A reduction of at least two score points of HE was observed in all patients after thirty days. There was a significant reduction on median (IQR) West Haven score from 3 (2-3) at baseline to 1 (0-1) after the procedure (p < 0.01). Twelve months survival was 63.6%. There was a decrease in median ammonia level from 106.5 (79-165) (ug/dL) to 56 (43-61) after SPSE (p = 0.006). The median mRS score before and after the procedure was 3 (3-5) and 1 (1-2.5), respectively (p < 0.01).

Conclusions: According to our experience, SPSE is a feasible and effective alternative to improve HE and functionality of patients with refractory EH.

Publication types

  • English Abstract

MeSH terms

  • Ammonia
  • Female
  • Hepatic Encephalopathy* / etiology
  • Hepatic Encephalopathy* / therapy
  • Humans
  • Liver Cirrhosis / complications
  • Male
  • Portasystemic Shunt, Transjugular Intrahepatic* / adverse effects
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Ammonia